COMMUNIQUÉS West-GlobeNewswire
-
aTyr Pharma Presents Preclinical Data for NRP2-Targeting Antibody ATYR2810 at the Connective Tissue Oncology Society (CTOS) 2026 Annual Meeting
19/11/2026 -
Remix Therapeutics Announces Updated Positive REM-422 Phase 1 Data in Adenoid Cystic Carcinoma at 2026 EORTC-NCI-AACR Symposium
19/11/2026 -
Korro to Participate in Upcoming Investor Conferences
19/11/2026 -
Adagene Announces First Patient Dosed in Phase 1 Study of ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager
19/11/2026 -
Evaxion announces strategy and business update and third quarter 2026 financial results
19/11/2026 -
In a Co-Managed Customer Support Model, Growing Companies Can Keep Control of Training While a Partner Runs Staffing
19/11/2026 -
Marker Therapeutics Awarded $16.2 Million CPRIT Grant to Advance MT-601 in Phase 2 APOLLO Study
19/11/2026 -
Verano Celebrates Grand Opening of MÜV Tarpon Springs, the Company’s 89th Florida Location, 166th Nationwide
19/11/2026 -
Opus Genetics Announces First Participant Dosed in Phase 1/2 Clinical Trial of OPGx-RDH12 Gene Therapy for Rare Inherited Childhood Blindness
19/11/2026 -
Enable Injections and ARespo Biopharma Announce Strategic Partnership
19/11/2026 -
J-Star Holding Expands Mitsubishi Chemical Partnership to Advance U.S. UAV Manufacturing and Domestic Carbon Fiber Supply Chain
19/11/2026 -
Axsome Therapeutics to Participate in Upcoming Investor Conferences
19/11/2026 -
Conavi Medical Highlights Commercial Launch and Significant Growth Potential in Shareholder Letter
19/11/2026 -
Medicus Pharma Regains Compliance with Nasdaq Minimum Equity Requirement for Continued Listing
19/11/2026 -
Palvella Therapeutics Announces QTORIN™ Docetaxel, a New QTORIN™ Program for the Treatment of Extramammary Paget’s Disease (EMPD)
19/11/2026 -
Clearmind Medicine Expands PTSD Patent Portfolio with Hong Kong Patent Application Publication
19/11/2026 -
Trading by management and close relations of management
19/11/2026 -
Actinogen pivotal Alzheimer’s disease trial demonstrates clinical benefit in older patients with mild to moderate disease, favorable safety profile and trends towards benefit in the overall population
19/11/2026 -
Humacyte Submits Supplemental Biologics License Application to FDA for the Acellular Tissue Engineered Vessel in Dialysis Access
19/11/2026
Pages